Prostaglandin-associated periorbitopathy syndrome (PAPS): Addressing an unmet clinical need.
Journal
Seminars in ophthalmology
Journal Volume
37
Journal Issue
4
Start Page
447
End Page
454
ISSN
1744-5205
Date Issued
2022-05-19
Author(s)
Sakata, Rei
Chang, Pei-Yao
Sung, Kyung Rim
Kim, Tae-Woo
Perera, Shamira A
Cantor, Louis B
Abstract
Background: Topical prostaglandin analogs (PGAs) are widely approved and preferred first-line options for glaucoma and elevated intraocular pressure (IOP). However, prostaglandin-associated periorbitopathy syndrome (PAPS) is now a well-recognized clinical and cosmetic concern for patients receiving PGAs, especially during long-term and unilateral therapy. PGA-associated periocular changes occur in a substantial proportion of patients, with older patients (>60 years) at greater risk of clinical presentation. PAPS may hinder long-term management of glaucoma, including treatment adherence, ophthalmic surgery outcomes, and reliable IOP measurements. Recommendation: New therapeutic approaches may address this unmet clinical need. Omidenepag isopropyl (OMDI) is a novel, non-prostaglandin, selective EP2 receptor agonist in ongoing development, which provides a unique pharmacological mechanism of action. OMDI appears to provide IOP reductions comparable to PGAs, but without PAPS-related undesirable effects. OMDI may offer a suitable long-term option for patients who demonstrate decreased efficacy, or failure, of PGAs, plus patients with significant PAPS, while fulfilling international guidelines.
Subjects
Omidenepag isopropyl
PAPS
PGA
glaucoma
periorbitopathy
Type
journal article